Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The druggable genome: an update.

Andreas P Russ1, Stefan Lampel

  • 1Genetics Unit, Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, UK. andreas.russ@bioch.ox.ac.uk

Drug Discovery Today
|December 27, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The GPS motif is a molecular switch for bimodal activities of adhesion class G protein-coupled receptors.

Cell reports·2012
Same author

Characterization and functional study of a cluster of four highly conserved orphan adhesion-GPCR in mouse.

Developmental dynamics : an official publication of the American Association of Anatomists·2012
Same author

Latrophilin signalling in tissue polarity and morphogenesis.

Advances in experimental medicine and biology·2011
Same author

The orphan adhesion-GPCR GPR126 is required for embryonic development in the mouse.

PloS one·2010
Same author

Latrophilin signaling links anterior-posterior tissue polarity and oriented cell divisions in the C. elegans embryo.

Developmental cell·2009
Same author

Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin.

Nature immunology·2005
Same journal

Organoid-AI platforms need integrated governance in drug discovery.

Drug discovery today·2026
Same journal

Inorganic nanoparticles for diagnostics, drug delivery and therapy for solid tumors.

Drug discovery today·2026
Same journal

HDAC11 as a potential therapeutic target for Alzheimer's disease.

Drug discovery today·2026
Same journal

From biologics to small-molecule modulators: The evolving landscape of interleukin-targeted therapeutics.

Drug discovery today·2026
Same journal

Targeting the GLP-1 receptor pathways for dual management of obesity and depression.

Drug discovery today·2026
Same journal

Chemical intervention strategies targeting MYC for cancer therapy.

Drug discovery today·2026
See all related articles

Annotating the druggable genome estimates the maximum potential for small-molecule drugs. This analysis excludes biologics and future scientific advancements, providing a focused view of current drug design possibilities.

Area of Science:

  • Genomics
  • Drug Discovery
  • Medicinal Chemistry

Background:

  • The druggable genome represents the set of human genes encoding proteins that can be modulated by small-molecule drugs.
  • Estimating the size of the druggable genome is crucial for understanding the scope of current drug development efforts.

Purpose of the Study:

  • To estimate the maximum potential size of the druggable genome for small-molecule drug design.
  • To define the boundaries of current therapeutic targets accessible by small molecules.

Main Methods:

  • Genome-wide analysis of protein targets.
  • Identification of proteins with drug-accessible binding sites.
  • Bioinformatic approaches to assess druggability.

Main Results:

Related Experiment Videos

  • The annotation provides an estimate of the maximum number of targets potentially addressable by small molecules.
  • This estimate serves as a benchmark for the current landscape of small-molecule drug discovery.

Conclusions:

  • The druggable genome concept offers a valuable framework for assessing the potential of small-molecule therapeutics.
  • This estimation is a snapshot and does not encompass biologics or future innovations in medicine and chemistry.